Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Chronic kidney disease

Nephrology · Known disease · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: 7 to 10% of the French population (HAS estimate) [1]; 6.2% of 18-69-year-olds, all stages combined, in the Constances cohort, and 3% of 18-84-year-olds at stages 3 to 5 [2]

Annual screening in at-risk patients

Laboratory tests

Urine tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Mild to moderate chronic kidney disease found (eGFR < 60), repeated at 3 months

Fasting sample.

Fasting laboratory tests

Urine tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Follow-up of stage 3A chronic kidney disease (eGFR > 45)

Fasting sample.

Fasting laboratory tests

Urine tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Follow-up of moderate stage 3B chronic kidney disease (eGFR between 30 and 44)

Fasting sample.

Twice-yearly tests

Fasting laboratory tests

Urine tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Follow-up of severe stage 4 chronic kidney disease (eGFR between 15 and 29)

Fasting sample.

Three-monthly tests

Fasting laboratory tests

Urine tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Follow-up of severe stage 5 chronic kidney disease (eGFR < 15)

Fasting sample.

Monthly tests

Fasting laboratory tests

Urine tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

After starting or increasing an ACE inhibitor, an ARB (ARB) or finerenone

Laboratory tests, 2 to 4 weeks after the change

Detailed explanation and international comparison (in French): read it in English (machine translation)

Also consider

Sources (15)
  1. Guide du parcours de soins – Maladie rénale chronique de l’adulte (MRC)
  2. Académie nationale de médecine. Dépistage, prévention et prise en charge de la maladie rénale chronique. Rapport adopté le 14 avril 2026 (Massy Z, Ronco P, Ardaillou R).
  3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024;105(4S):S117-S314.
  4. National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management. NICE guideline NG203, publiée le 25 août 2021, mise à jour le 24 novembre 2021 (recommandations 1.1.20 à 1.1.24, 1.2.5, 1.3.4 et tableau 2, 1.5.5, 1.6.14, 1.6.18, 1.6.19, 1.7.3, 1.7.4, 1.12.1, 1.12.2 et 1.12.8, et leur justification).
  5. Kidney Health Australia. Chronic Kidney Disease (CKD) Management in Primary Care. 5e édition. Melbourne : Kidney Health Australia ; 2024 (manuel destiné à la médecine générale).
  6. US Preventive Services Task Force (Moyer VA). Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(8):567-70 (recommandation I ; déclarée périmée sur le site de l’USPSTF, mise à jour en cours, page consultée le 29/10/2026).
  7. Qaseem A, Hopkins RH Jr, Sweet DE, Starkey M, Shekelle P ; Clinical Guidelines Committee of the American College of Physicians. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159(12):835-47.
  8. Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in CKD Work Group. KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int. 2022;102(6S):S129-S205.
  9. Société francophone de néphrologie, dialyse et transplantation (SFNDT), Commission Néphrologie clinique. Fiche complète vaccination et maladie rénale chronique, juin 2024.
  10. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 0591 (urée) et 2002 (coefficient de saturation de la transferrine).
  11. Institut national d'excellence en santé et en services sociaux (INESSS). Utilisation judicieuse des analyses biomédicales : dosage de l'urée sérique pour l'évaluation de la fonction rénale. Québec, septembre 2026.
  12. Babitt JL, Berns JS, Bozkurt B, et al. Executive summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney Int. 2026;109(1):44-56.
  13. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 0983 (parathormone) et 1139 (25-OH-vitamine D).
  14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2017;7(1):1-59.
  15. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 4500 (dépistage et/ou diagnostic d'une hépatite B).